Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02978625|
Recruitment Status : Recruiting
First Posted : December 1, 2016
Last Update Posted : July 21, 2022
|Condition or disease||Intervention/treatment||Phase|
|Adenoid Cystic Skin Carcinoma Adnexal Carcinoma Anaplastic Large Cell Lymphoma, ALK-Negative Anaplastic Large Cell Lymphoma, ALK-Positive Apocrine Carcinoma Cylindrocarcinoma Digital Papillary Adenocarcinoma Endocrine Mucin-Producing Sweat Gland Carcinoma Extramammary Paget Disease Extraocular Cutaneous Sebaceous Carcinoma Hidradenocarcinoma Keratoacanthoma Malignant Sweat Gland Neoplasm Merkel Cell Carcinoma Microcystic Adnexal Carcinoma NK-Cell Lymphoma, Unclassifiable Papillary Adenocarcinoma Porocarcinoma Primary Cutaneous Mucinous Carcinoma Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Recurrent T-Cell Non-Hodgkin Lymphoma Refractory Anaplastic Large Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Refractory Merkel Cell Carcinoma Refractory Mycosis Fungoides Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Skin Squamous Cell Carcinoma Refractory T-Cell Non-Hodgkin Lymphoma Sezary Syndrome Signet Ring Cell Carcinoma Skin Basal Cell Carcinoma Skin Basosquamous Cell Carcinoma Skin Squamous Cell Carcinoma Spiradenocarcinoma Squamoid Eccrine Ductal Carcinoma Squamous Cell Carcinoma of Unknown Primary Sweat Gland Carcinoma Trichilemmal Carcinoma Vulvar Squamous Cell Carcinoma||Other: Laboratory Biomarker Analysis Biological: Nivolumab Biological: Talimogene Laherparepvec||Phase 2|
I. To determine the frequency of patients responding (response rate) to talimogene laherparepvec monotherapy.
I. To determine the local response rate to talimogene laherparepvec in injected tumors.
II. To determine the response rate to talimogene laherparepvec + nivolumab (NIVO).
III. To identify potential pre-treatment and on-treatment correlative biomarkers of local and systemic immune response.
Patients receive talimogene laherparepvec intratumorally (IT) and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 12 weeks for 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||68 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors|
|Actual Study Start Date :||September 18, 2017|
|Estimated Primary Completion Date :||June 1, 2023|
|Estimated Study Completion Date :||June 1, 2023|
Experimental: Treatment (talimogene laherparepvec, nivolumab)
Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Biological: Talimogene Laherparepvec
- Response rate to talimogene laherparepvec alone (Part I) [ Time Frame: Up to 1 year ]Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Best overall response rate to talimogene laherparepvec and nivolumab combination therapy (Part II) [ Time Frame: Up to 1 year ]Will be assessed by RECIST version 1.1.
- Durable response rate [ Time Frame: Up to 1 year ]Will be defined as complete response or partial response lasting >= 6 months.
- Response rate by cancer type [ Time Frame: Up to 1 year ]Will be assessed by RECIST version 1.1.
- Response rate of injected lesions [ Time Frame: Up to 1 year ]Will be assessed by RECIST version 1.1.
- Response rate of non-injected lesions [ Time Frame: Up to 1 year ]Will be assessed by RECIST version 1.1.
- Frequency of curative surgery (unresectable lesion becomes resectable) [ Time Frame: Up to 1 year ]
- Progression free survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed at 1 year ]
- Progression free survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed at 2 years ]
- Overall survival [ Time Frame: At 1 year ]
- Overall survival [ Time Frame: At 2 years ]
- Incidence of adverse events [ Time Frame: Up to week 24 ]Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
- Change in herpes simplex virus (HSV) serostatus assessed in blood specimens [ Time Frame: Baseline to week 6 ]Will be analyzed using descriptive statistics. A test of proportions will be performed.
- Biomarker analysis of %PD-L1, flow cytometry for HVEM, NECTIN1/2, and IDO, tryptophan and L-kynurenine, cytokine levels, Nanostring, number of non-synonymous mutations, and % T-cell receptor (TCR) clonality [ Time Frame: Up to 1 year ]Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed.
- Biomarker analysis of necrosis and Nanostring [ Time Frame: Up to 1 year ]Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed.
- Biomarker analysis of herpes simplex virus (HSV) status, Merkel cell polyomavirus status, and PD-L1 status [ Time Frame: Up to 1 year ]Will be analyzed using descriptive statistics. Test of proportions and logistic regression will be performed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02978625
|Principal Investigator:||Ann (Annie) W Silk||Dana-Farber - Harvard Cancer Center LAO|